000			04074cam a2200421Mi 4500
988			_aSpringer_Medicine_2017
999			_c96385 _d96385 _x1
001			96385
003			ES-MaUEC
005			20230102112751.0
006			m o d
007			cr |n|||||||||
008			170804s2017 sz o 000 0 eng d
020			_a3319547410 _q(electronic bk.)
020			_a9783319547411 _q(electronic bk.)
020			_z3319547402
020			_z9783319547404
040			_aYDX _cYDX _dN$T _dEBLCP _dNJR _dKOS _dGW5XE _dKOS _dN$T _dOCLCO _dUAB _dOCLCO _dYDX _dESU _dAZU _dUPM _dIOG _dCOO _dOH1 _dOCLCQ _dMERER _dVT2 _dOCLCQ _dOCLCO _dOCLCA _dMERUC _dOCLCO _dES-MaUEC _bspa
050		4	_aRC280 _b2017 EB
245	0	0	_aPET/CT in melanoma _cMichael S. Hofman, Rodney J. Hicks, editors
264		1	_aCham, Switzerland _bSpringer _c2017
300			_a1 recurso en línea
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF
490	0		_aClinicians' guides to radionuclide hybrid imaging, PET/CT
500			_aSpringerLink
505	0		_aForeword; Preface; Acknowledgements; Contents; Contributors; 1: Melanoma; 1.1 Clinical Features; 1.2 Biopsy of the Lesion; 1.3 Classification; 1.3.1 Superficial Spreading Melanoma; 1.3.2 Nodular Melanoma; 1.3.3 Lentigo Maligna Melanoma (LMM); 1.3.4 Acrolentiginous Melanoma (ALM); 1.4 Classification/Staging; References; 2: Pathology of Melanoma; 2.1 Histopathology; 2.2 Sentinel Lymph Node Biopsy; 2.3 Synoptic Reporting of Melanoma; 2.4 Molecular Analysis; References; 3: Management of Melanoma; 3.1 Surgical Management of Primary Melanoma; 3.2 Sentinel Lymph Node Biopsy.
505	8		_a3.3 Management of Locoregional Recurrent Melanoma3.4 Radiotherapy; 3.5 Adjuvant Systemic Therapy of Melanoma; 3.6 Management of Metastatic Melanoma; 3.6.1 Targeted Systemic Therapy with MAPK Pathway Inhibition; 3.6.2 Immunotherapy; 3.6.3 Cytotoxic Chemotherapy; References; 4: Radiological Imaging in Melanoma; 4.1 Introduction; 4.2 Plain Radiographs; 4.3 Ultrasound; 4.4 Computerised Tomography (CT); 4.5 MRI; 4.6 Restaging Imaging; References; 5: Role of PET/CT in Melanoma; 5.1 Introduction; 5.2 Primary Diagnosis/Staging; 5.2.1 Sentinel Lymph Node Scintigraphy with SPECT/CT.
505	8		_a5.2.2 Sentinel Lymph Node Positive5.2.3 High-Risk Patients with Stage I or II Disease; 5.2.4 Stage III and IV Melanoma; 5.2.5 Limitations of FDG PET/CT; 5.3 Response Assessment; 5.3.1 Pitfalls; 5.3.2 Treatment Related Adverse Effects Mimicking Malignancy; 5.4 Surveillance; 5.5 Beyond FDG PET/CT; References; 6: PET/CT in Melanoma (Additional Teaching Cases); References; Index.
520	3		_aThis pocket book provides up-to-date guidance on the use of PET/CT in patients with melanoma, which is of rapidly growing importance due to the emergence of immunotherapy. The role of PET/CT in diagnostic workup, staging, treatment selection, prognostication, and follow-up is clearly explained. Imaging features are described and illustrated with the aid of a series of teaching cases, and attention is drawn to normal variants, artifacts, and pitfalls. Readers will also find explanation of the relation of the clinical and pathological background to imaging and the value of PET/CT compared with conventional radiological imaging. The book is published within the Springer series Clinicians' Guides to Radionuclide Hybrid Imaging (compiled under the auspices of the British Nuclear Medicine Society) and will be an excellent asset for referring clinicians, nuclear medicine physicians, radiologists, radiographers, technologists, and nurses who routinely work in nuclear medicine and participate in multidisciplinary meetings.
650		7	_2embne _9143713 _aMelanoma
700	1		_aHicks, Rodney J.
700	1		_aHofman, Michael S.
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-54741-1 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b02/2019 _dz _ea _zSI